CVM 8-K: Regulatory action

CEL-SCI Corporation

Filed with the SEC on · accession 0001654954-26-010013

CVM filed a 8-K (current report) with the SEC on Nov 20, 2026. CEL-SCI Corporation announced that its investigational cancer immunotherapy Multikine received official designation under the Saudi Food and Drug Authority's New Accelerator Program for Drugs in Rare Diseases (NADR), with a Marketing Authorization Application planned within 2-3 months and potential…

Summary of the filing

CEL-SCI Corporation announced that its investigational cancer immunotherapy Multikine received official designation under the Saudi Food and Drug Authority's New Accelerator Program for Drugs in Rare Diseases (NADR), with a Marketing Authorization Application planned within 2-3 months and potential commercial launch in 2027 or early 2028.

Key details

Registrant, developer of multikineCEL-SCI Corporation
Regulatory authority granting nadr designationSaudi Food and Drug Authority (SFDA)
In-country regulatory and commercialization partner in saudi arabiaAmarox
Chief executive officer of cel-sciGeert Kersten
Founder and chief executive officer of saudi amaroxDr. Abdullah Alzomaie

✦ Ask GOAX AI about this filing — what it means for CVM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CVM?

Click here

Frequently asked questions

What did CVM file with the SEC on Nov 20, 2026?

CVM filed a 8-K (Regulatory action). CEL-SCI Corporation announced that its investigational cancer immunotherapy Multikine received official designation under the Saudi Food and Drug Authority's New Accelerator Program for Drugs in Rare Diseases (NADR), with a Marketing Authorization Application planned within 2-3 months and potential commercial launch in 2027 or early 2028.

What does a regulatory action mean for CVM stock?

A settlement removes uncertainty; the stock often reacts to whether the amount is bigger or smaller than investors expected.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other CVM SEC filings

Get alerts when CVM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days